Scribe Therapeutics (SCTX) Earnings Forecast
Analysts expect Scribe Therapeutics (SCTX) to lose $3.68 a share in FY26, the average of 2 estimates as of Nov 17, 2026.
- FY26 consensus EPS
- $−3.68
- 2 analysts
- FY27 consensus EPS
- $−2.52
- 2 analysts · low $−3.81, high $−1.72
- Disagreement, FY26
- $3.05
- wide, $−5.56 to $−2.52
Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.
Analysts expect Scribe Therapeutics to lose $4.65 a share in FY28; 2 analysts publish an estimate for FY28.
Are estimates going up or down lately?
Our record of this company's consensus starts with tonight's snapshot. A revision needs two of our own nightly snapshots of one fiscal period to compare, and nothing before the first is reconstructed, because a backfilled revision is a number we never observed.
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
If the Street is right, what does that imply for the share price?
EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from the first positive year on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.
The arithmetic will run: EBITDA times your multiple is an enterprise value, plus $0.2B net cash and divided by 0.01B diluted shares, which is a price a share. Net cash from the Sep 30, 2026 balance sheet, diluted shares from the Sep 30, 2026 filing.
This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.
What you pay for the growth
Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.
How much do analysts disagree?
For FY28, estimates run from $−6.27 to $−3.02 around an average of $−4.65, drawn by 2 analysts.
A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.
Is next quarter a high bar or an easy one?
Analysts expect Scribe Therapeutics to lose $0.65 a share in the December quarter, the one estimate published. We hold no expected date for the next report.
For the March quarter, analysts expect a loss of $0.63 a share.
Does Scribe Therapeutics usually beat or miss?
We have not been able to check a quarter yet. We hold no estimate for Scribe Therapeutics yet, so this record starts on the night we first do.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. A quarter we did not hold an estimate for is never filled in after the fact.
Where the growth comes from
The Street expects sales to grow −35.3% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.
Coverage, and the gap to the filing
2 analysts publish an EPS estimate for FY26 and 3 publish revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by yearHide the coverage chart
The full consensus, year by year
Coverage thins with distance: 3 revenue estimates for FY26, 3 for FY28.
Out-year bands widen as fewer analysts publish: 2 EPS estimates for FY26, 2 for FY28.
| Fiscal year | Revenue $B | YoY | EPS $ | YoY | EBITDA $B | Net inc. $B | Shares B | Analysts rev · EPS | Fwd P/E |
|---|---|---|---|---|---|---|---|---|---|
| FY26E | 0.00.0 to 0.0 | n/ca | −3.68−5.56 to −2.52 | n/ca | −0.1 | −0.1 | 0.02 | 3 · 2 | n/m |
| FY27E | 0.00.0 to 0.0 | ▼35.3% | −2.52−3.81 to −1.72 | — | −0.0 | −0.0 | 0.02 | 3 · 2 | n/m |
| FY28E | 0.00.0 to 0.0 | ▲4.4% | −4.65−6.27 to −3.02 | — | −0.1 | −0.1 | 0.02 | 3 · 2 | n/m |
Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 2 EPS estimates for FY26, 3 for revenue. Not investment advice.
Common questions
What do analysts expect Scribe Therapeutics to earn in FY26?
Analysts expect Scribe Therapeutics to lose $3.68 a share in FY26, the average of 2 estimates as of Nov 16, 2026.

